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Abstract
Background: Variation in development methods of Pressure Ulcer Risk Assessment Instruments has led to inconsistent
inclusion of risk factors and concerns about content validity. A new evidenced-based Risk Assessment Instrument, the
Pressure Ulcer Risk Primary Or Secondary Evaluation Tool - PURPOSE-T was developed as part of a National Institute for
Health Research (NIHR) funded Pressure Ulcer Research Programme (PURPOSE: RP-PG-0407-10056). This paper reports
the pre-test phase to assess and improve PURPOSE-T acceptability, usability and confirm content validity.
Methods: A descriptive study incorporating cognitive pre-testing methods and integration of service user views was
undertaken over 3 cycles comprising PURPOSE-T training, a focus group and one-to-one think-aloud interviews. Clinical
nurses from 2 acute and 2 community NHS Trusts, were grouped according to job role. Focus group participants used
3 vignettes to complete PURPOSE-T assessments and then participated in the focus group. Think-aloud participants
were interviewed during their completion of PURPOSE-T.
After each pre-test cycle analysis was undertaken and adjustment/improvements made to PURPOSE-T in an iterative
process. This incorporated the use of descriptive statistics for data completeness and decision rule compliance and
directed content analysis for interview and focus group data. Data were collected April 2012-June 2012.
Results: Thirty-four nurses participated in 3 pre-test cycles. Data from 3 focus groups, 12 think-aloud interviews
incorporating 101 PURPOSE-T assessments led to changes to improve instrument content and design, flow and
format, decision support and item-specific wording. Acceptability and usability were demonstrated by improved
data completion and appropriate risk pathway allocation. The pre-test also confirmed content validity with clinical
nurses.
Conclusions: The pre-test was an important step in the development of the preliminary PURPOSE-T and the
methods used may have wider instrument development application. PURPOSE-T proposes a new approach to
pressure ulcer risk assessment, incorporating a screening stage, the inclusion of skin status to distinguish between
those who require primary prevention and those who require secondary prevention/treatment and the use of
colour to support pathway allocation and decision making. Further clinical evaluation is planned to assess the
reliability and validity of PURPOSE-T and it’s impact on care processes and patient outcomes.
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Public Involvement (PPI)
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Background
Pressure ulcers (PUs) are defined as ‘localised injury to
the skin and/or underlying tissue usually over a bony
prominence, as a result of pressure, or pressure in com-
bination with shear’ [1]. They have a negative effect on
patients quality of life [2, 3] and are costly to health care
organisations world wide [4–7].
It is not appropriate to prevent PUs by subjecting all
patients, including those not at risk to resource intensive
interventions (such as repositioning by nurses, expensive
mattresses), as these may impact on their quality of life
(by disturbing sleep, for example) and divert nursing time
from other essential areas [8]. Therefore we must target
care appropriately, which is achieved by assessing the pa-
tient for the presence of PU risk factors (e.g. immobility,
poor skin status, or poor perfusion), a process known as
risk assessment. Risk assessment is considered the corner-
stone to PU prevention and is recommended by inter-
national and national PU prevention guidelines [8–11]. To
support clinical practice, Risk Assessment Instruments
(RAIs) have been developed and are commonly used to
systematically identify patients at risk, in preference to
clinical ‘judgement’ of risk alone, despite the lack of evi-
dence of their clinical effectiveness [1, 9, 10, 12, 13].
The theoretical basis of instrument development has
grown over the last 30 years leading to the development
and validation of a wide range of instruments designed
to measure health status and quality of life [14]. Gold
standard instrument development methods focus upon
ensuring content validity and a conceptual framework,
with testing and evaluation to establish psychometric prop-
erties including content, construct, convergent, discrimin-
ant, known group, criterion and concurrent validity, and
inter-rater, intra-rater and test retest reliability [14–17]. In
addition, as RAIs aim to predict those at risk of PU devel-
opment it has been argued [18–20], much like other clin-
ical prediction models (e.g. a predictive instrument to
estimate the risk of mortality following cardiovascular sur-
gery [21]), that their content needs to be informed by mul-
tivariable modelling with subsequent model testing on a
‘new’ prospective target population [22]. Establishing
content validity is fundamental and needs to be a key
consideration, as subsequent testing of other measure-
ment properties will not replace or rectify problems with
content validity [17]. Attention should also be given to the
usability and acceptability of the instrument to users and
patients. This is considered important in the development
of instruments to facilitate content validity and ensure
they are relevant, and understandable to the target popu-
lation [14, 16, 17, 23–26].
Limitations of existing RAIs were identified following
a systematic review of the risk factor literature [27] and
a review of the content, development and testing of the
14 RAIs [16] included in the recent NICE review [10].
The instruments were developed for varying patient
populations including acute hospital, intensive-care
units, rehabilitation units and nursing homes. The re-
view [16] identified that many instruments were devel-
oped decades ago when there was a paucity of PU risk
factor evidence and a lack of methodological guidance
for instrument development and evaluation [16]. Only
two instruments reported a conceptual framework [28,
29] and the majority of instruments (n = 11) were devel-
oped on the basis of clinical opinion and/or literature
review, or adaptations of original instruments [30–39].
The remaining 3 instruments were developed using
statistical modelling methods, but are limited by the use
of single centre populations, inadequate sample sizes
and/or use of the same data set for development and
validation [29, 40, 41]. These limitations have led to in-
consistent inclusion of risk factors across instruments
[16] and raise concern about their content validity. In
addition, there is limited evidence that instrument de-
velopers involved the population of intended users, such
as people at risk of pressure ulceration [16].
To address these limitations, a new evidence-based RAI,
the PU Risk Primary Or Secondary Evaluation Tool -
PURPOSE-T was developed as part of a National Institute
for Health Research (NIHR) funded Programme Of
Research (PURPOSE: RP-PG-0407-10056). The develop-
ment of PURPOSE-T comprised 5 phases and incorpo-
rated innovative service user involvement:
1. Systematic review of epidemiological literature to
identify risk factors associated with increased
probability of PU development [27].
2. Consensus study incorporating an international
expert group, evidence review and service user views
to agree the risk factors, assessment items and
structure of PURPOSE-T [42].
3. Proposal of a new PU conceptual framework to
show the critical determinants of PU development
and theoretical causal pathway and to underpin
PURPOSE-T [43].
4. Design and pre-testing of the draft PURPOSE-T to
confirm content validity assess and improve the
acceptability and usability [8].
5. Clinical evaluation of 230 patients from acute and
community settings to assess reliability, validity
(convergent and known groups), data completeness
and clinical usability [8].
The first 3 phases of this work and the support of a
graphic designer underpinned the development of the
initial draft of PURPOSE-T, comprising a 3-step risk as-
sessment process. In Step 1, a screening stage, the pa-
tient’s mobility and skin status are assessed with yes/no
items and one of two decisions are made: not at risk OR
Coleman et al. BMC Medical Research Methodology  (2016) 16:158 Page 2 of 13
potentially or definitely at risk - hence continue to Step 2.
In Step 2, a full assessment stage, 7 risk factors of Immo-
bility, PU and Skin Status, Perfusion, Diabetes, Moisture,
Sensory perception and Nutrition are assessed using
yes/no items. The items in Step 1 and 2 are colour coded
and based upon the responses and colour coding for each
item the assessor is required, in Step 3, to identify one of
three decision pathways: secondary prevention and treat-
ment pathway (for those with an existing PU or with scar-
ring from a previous PU); primary prevention pathway
(for those at risk of a PU) OR; not currently at risk path-
way [16]. The final version of PURPOSE-T can be accessed
via: http://medhealth.leeds.ac.uk/accesspurposet.
This paper describes the phase 4 pre-test and high-
lights the impact of including a pre-test stage as part of
the instrument development process.
Aims
The aim was to assess and improve the acceptability, us-
ability, format, design, clarity, comprehension, language
and data completeness of the draft PUPROSE T with
clinical nurses [8]. While content validity was a key con-
sideration of the consensus study, the pre-test also aimed
to confirm the content validity with intended end users,
clinical nurses.
Methods
The pre-test involved cognitive pre-testing methods to
evaluate how clinical nurses interpreted questions, re-
sponse categories and instructions while using the draft
PURPOSE-T [8, 44], and innovative integration of service
user views via the PU Research Service User Network
(PURSUN UK: http://www.pursun.org.uk/) including co-
development of vignettes to facilitate pre-testing and the re-
view of PURPOSE-T following pre-testing. Cognitive pre-
testing methods are well established in the development of
health status and patient reported outcome measures and
are considered important for improving precision, confirm-
ing content validity and ensuring the instrument is under-
stood and relevant to the target population [14, 17, 25, 26].
The specific pre-testing methods used in this study
incorporated focus groups and one-to-one think-aloud
interviews. A focus group is a group interview which
incorporates group interaction as part of the method
and is useful in exploring peoples, knowledge, attitudes
and experience [45]. One-to-one think-aloud interviews
encourage participants to vocalise their thoughts or
‘think-aloud’ while they are concurrently undertaking a
task [46], in this case completion of the PURPOSE-T.
The use of both focus groups and one-to-one think-
aloud interviews was considered appropriate, as it was
anticipated that the focus groups would allow more gen-
eral usability issues to be identified e.g. relating to the
implementation of PURPOSE-T, while the think-aloud
interviews would allow more specific item issues to be
identified e.g. difficulties in understanding the wording
of items within PURPOSE-T [47, 48]. Both would aid
instrument development and eventual implementation.
The pre-test study was conducted over three cycles each
comprising participant training in the use of the draft
PURPOSE-T, followed by a focus group and one-to-one
think-aloud interviews (Fig. 1). Purposive sampling was
undertaken to ensure that Tissue Viability Nurses (TVNs),
Staff Nurses (SN) and Sisters/charge nurses) with an inter-
est in tissue viability (e.g. a link nurse or member of a local
PU or wound care working group), from 2 acute (1 district
general hospital and 1 large teaching trust) and 2 commu-
nity NHS Trusts in West Yorkshire UK, were grouped ac-
cording to job role (cycle 1: TVNs; cycle 2: SN; cycle 3:
Sister/Charge Nurses) [8]. It was anticipated that this
would facilitate openness, as heterogeneous groups can
lead to inhibition in raising issues that do not seem to
be shared by others [8, 49, 50]. This was thought to be
particularly important for this group as a hierarchy
might have stifled disclosure (e.g. a staff nurse might not
want to disagree with the views of their Sister/Charge
Nurse) [8]. Having nurses from different centres minimised
familiarity which can lead to participants relying on ‘taken
for granted’ assumptions [8, 50].
In each pre-test cycle 3 focus groups comprising four
to eight nurses [45] was undertaken to allow important
general themes [51] associated with the implementation
of PURPOSE-T to be identified. In addition, we estimated
that approximately 4 think- aloud interviews for each of
the three pre-test cycles (each interview incorporating the
completion of 3 PURPOSE-T assessments using different
vignettes) were needed to reach saturation, with no new
issues arising. This was slightly lower than cognitive
interviewing guidance for questionnaire development
indicating a suitable sample size of 5–15 individuals per
interviewing round [48], but this sample size was thought
to be sufficient in light of the low number of data items in
the PURPOSE-T and the concurrent focus group data
collection.
After each pre-test cycle, analysis was undertaken and
the results reviewed by a clinical/academic Working
Group (authors) who agreed adjustment/improvements
to the draft PURPOSE-T. These were implemented in
the next cycle in an iterative process (Fig. 1). Following
the final pre-test cycle, PURPOSE-T was reviewed by
PURSUN UK members who comprise patients and carers
with direct experience of living with PUs or PU risk.
PURSUN was set up to improve the quality of Patient
and Public Involvement (PPI) in PU research. PURPOSE-
T was also reviewed at a meeting of the international
expert group (comprising clinical/academic experts in the
PU field including nurses, doctors, bioengineers, an epidemi-
ologist, and individuals with organisational development and
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clinical decision making expertise) involved in the earlier
instrument development consensus study phase [42].
Data collection
Data collection was undertaken between April 2012 and
June 2012. The pre-tests were held away from the clin-
ical area in a comfortable university setting, lasted 2.5 h
in total with refreshments available throughout [45]. The
initial training, undertaken by all participants involved a
short presentation and demonstration of how to use the
draft PURPOSE-T with a simulated patient [8]. Each
nurse then completed the draft PURPOSE-T using simu-
lations of real patient situations via written vignettes.
The vignettes were case studies comprising key patient
characteristics pertinent to PU risk assessment and
were designed to allow participants to practice using
PURPOSE-T and to prompt study participant responses
[52] while undertaking think-aloud interviews or focus
groups [8]. These were accompanied by photographs of
PUs and were appropriate to the nurses’ area of practice
(i.e. community nurses used vignettes of community pa-
tients) [8]. The vignettes comprised 7 acute and 7 commu-
nity case studies and were co-developed by the researcher
(SC), the Working Group and members of PURSUN prior
to the pre-test to ensure they were realistic and clinically
relevant. They incorporated a range of patients including
those not currently at risk, those at risk and those with
existing PUs to maximise the potential of identifying
usability issues with PURPOSE-T over the course of the
pre-test [8].
Nurse participants were then assigned to either a focus
group or a one-to-one think-aloud interview which
were audio-recorded to allow analysis to facilitate the
development PURPOSE-T. The assignment to a focus
group or a one-to-one think-aloud interview was under-
taken randomly to make it fair to participants, as it was
anticipated that the focus groups would be favoured by
nurses. Those allocated to the focus group were asked to
independently complete PURPOSE-T again, using 3 of the
7vignette case studies relevant to their area of practice
prior to the focus group meeting. The specific vignettes
were assigned to each nurse to ensure all 7 were used by
at least 1 participant at each focus group. Nurse partici-
pants were encouraged to highlight any areas they found
confusing on the PURPOSE-T form. A co-facilitator
assessed data completeness and listed areas where data
items were not completed or not completed as required,
as well as areas noted by the nurses as confusing [8]. The
focus group meeting then convened to discuss the use of
PURPOSE-T. The facilitator (SC) promoted group inter-
action and guided discussions around a topic guide, which
considered the usability and areas of confusion regarding
the use of PURPOSE-T, as well as any anticipated prob-
lems with using it in clinical practice [8]. This was in-
formed by the data completeness assessment.
Up to four different nurses from each pre-test cycle
were randomly assigned to the one-to-one think-aloud
interview. A researcher (EMc or DM) conducted the in-
terviews around a topic guide. Firstly, the nurse partici-
pants were guided through the think-aloud technique.
Once the nurses were content with the approach, they
were asked to complete PURPOSE-T again using 3 of
the 7 vignette case studies appropriate to their area of
practice in the presence of the researcher. The specific
vignettes were assigned to each nurse to ensure all 7
were used by at least 1 think-aloud participant at each
Fig. 1 Pre-test Cycles
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pre-test cycle. The researcher encouraged the nurses to
vocalise their thoughts as they completed the PURPOSE-
T and were able to probe less vocal participants concur-
rently or retrospectively regarding completions of the task
[8, 46, 48]. Potential scripted probes were prepared in ad-
vance, but interviewers were also at liberty to use spontan-
eous probes as relevant to the particular interview.
Ethical considerations
The study was reviewed for potential ethical hazards and
approved by a University of Leeds Ethics Committee. In-
formed consent was obtained prior to study participation
and participants were free to withdraw from the study
without giving reasons.
Data analysis
To assess data completeness and compliance with deci-
sion rules, PURPOSE-T assessments were analysed using
descriptive statistics after each pre-test cycle for assess-
ments where only Step 1 (Screening) were completed
and assessments where both Step 1 (Screening) and Step
2 (Full Assessment) were completed. Summaries included:
number and percent of item level missing data; number
and percent of risk categories allocated and; number and
percent items missing where a risk category had been
allocated.
Focus group meetings and the think-aloud interviews
were transcribed verbatim. The researcher (SC) listened
to the audio-tapes and read the transcripts to ensure ac-
curacy and that they had a good overview of the focus
group discussions and one-to-one think-aloud interviews
[8]. The data was then manually coded by the researcher
(SC) with initial categories based on the items of the
draft PURPOSE-T, using a directed content-analysis ap-
proach [53] with additional codes being added as they
emerged from the data. This was reflected in summary re-
ports, which were reviewed by the focus group facilitators
and the think-aloud researchers to ensure it reflected dis-
cussions/interviews [8]. The emphasis was on identifying
themes about content, format, design, comprehension and
language across the focus groups and think-aloud inter-
views which impacted on the acceptability, data complete-
ness and usability of PURPOSE-T in clinical practice.
Results
Over the three pre-test cycles 34 nurses from acute (n =
16) and community settings (n = 18) participated. Table 1
details the characteristics of the nurses involved.
At each pre-test cycle, four nurses undertook think-
aloud interviews (12 nurses over the 3 pre-test cycles)
and seven or eight nurses attended the focus groups (22
nurses over the 3 pre-test cycles) [8]. They completed
101 PURPOSE-T assessments using vignette case studies;
in the first pre-test 11 TVN/Research Nurses undertook
32 PURPOSE-T assessments, in the second pre-test 12
staff nurses undertook 36 PURPOSE-T assessments and
in the third pre-test 11 Sisters undertook 33 PURPOSE-
T assessments [8].
Changes made to the PURPOSE-T between pre-test
cycles are summarised in Fig. 2 and include three main
areas:
 flow and format, i.e. colour coding, layout and order
of assessment items.
 decision support, i.e. instructions to facilitate
appropriate assessment and pathway allocation.
 wording of specific items.
The majority of changes were made following pre-test
cycle 1, with ongoing refinement following pre-test cycle
Table 1 Demographic details of pre-test participants
Pre-Test Session 1 (TVN/RNs) Pre-Test Session 2 (Staff Nurse) Pre-Test Session 3 (Sisters) Overall/total
N:11 N: 12 N: 11 N: 34














































DN Practice educator: 2
N Number, DGH District General Hospital Trust, THT Teaching Hospitals Trust, CT Community Trust, DN District Nurse, CL Clinical Lead, SN Staff Nurse, SM Staff Midwife
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2 and minimal adjustments following pre-test cycle 3
(Fig. 2). The qualitative and quantitative data were inter-
preted simultaneously in order to understand the impact
of the format, flow, decision support and wording upon
data completeness to inform amendments to the draft
instrument [8]. For example, the data completeness as-
sessment in the first pre-test (Tables 2 and 3 and Figs. 3
and 4) showed high levels of missing data and poor levels
of decision pathway allocation [8]. The corresponding focus
group discussions highlighted confusion about where to
indicate pathway allocation: I think putting the ta-
bles here seperates the key discussion points.
Focus group participant - ‘yes I got to that point [the
assessment decision section] and then finished it and ig-
nored those boxes at the bottom really’.
Some nurses had attempted to indicate a pathway
though they were clearly unsure of where to do this. This
brought to light a significant omission and lack of clarity
Fig. 2 Changes to PURPOSE-T following each pre-test sessions [8]
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Table 2 Item level completion for assessments that included step 1 (screening) and step 1 (screening) and 2 (full assessment) [8]














Item level completion for assessments that included step 1 (screening)
Mobility 4 100% (24/24) At least 1 of 4 100% (10/10) At least 1 of 4 100% (8/8)
Skin/PU status 2 66.7% (8/12) At least 1 of 4 90% (9/10) At least 1 of 4 100% (8/8)
Decision pathway allocated 1 0% (0/6) 1 100% (10/10) 1 87.5% (7/8)
Total Item completion - 76.2% (32/42) - 96.7% (29/30) - 95.8% (23/24)
Total Item completion where decision pathway
allocated
- 0% - 96.7% (29/30) - 100% (21/21)
Item level completion for assessments that included step 1 (screening) and 2 (full assessment)
Mobility (1st stage) 4 93.3% (97/104) At least 1 of 4 96.2% (25/26) At least 1 of 4 100% (25/25)
Skin/ PU status (1st stage) 2 98.1% (51/52) AA 100% (3/3) AA 100% (1/1)
Movement Matrix 1 100% (26/26) 1 100% (26/26) 1 96% (24/25)
Sensory Perception 1 96.2% (25/26) 1 of 2 100% (26/26) 1 of 2 100% (25/25)
Current DSA - listed sites 15 71.5% (279/390) 13 75.4% (255/338) 13 97.2% (316/325)
Current DSA – other sites AA 0% (0/0) AA 50.0% (1/2) AA 0% (0/0)
Current PU AA 84.2% (16/19) AA 83.3% (20/24) AA 80.0% (20/25)
Previous PU history AA 75% (9/12) AA 77.8% (7/9) 1 of 2 (if yes 3, AA) 85.3% (29/34)
Scarring 2 55.8% (29/52) AA 100% (1/1) AA 100% (1/1)
Perfusion 2 92.3% (48/52) At least 1 of 3 73.1% (19/26) At least 1 of 3 100% (25/25)
Nutrition 4 76.9% (80/104) At least 1 of 5 100% (26/26) At least 1 of 5 100% (25/25)
Moisture 1 (if yes 2 as applicable) 74.1% (40/54) 1 of 3 84.6% (22/26) 1 of 3 100% (25/25)
Diabetes 1 100% (26/26) As applicable 100% (5/5) 1 of 2 100% (25/25)
Decision pathway allocated 1 of 3 53.8% (14/26) 1 of 3 96.2% (25/26) 1 of 3 100% (25/25)




- 83.7% (417/498) - 83.7% (452/540) - 96.6% (566/586)
















within the PURPOSE-T, and the need to include a response
box within the ‘not currently at risk’ pathway at step 1 of
the assessment, and to make the pathway allocation re-
sponse box at step 3 of the assessment more obvious [8].
The think-aloud interviews in the first pre-test session
highlighted a complementary issue relating to the deci-
sion support and the ordering of the decision pathway
boxes in the first draft PURPOSE-T. The original order
was a blue ‘not currently at risk pathway’ on the left, an
amber ‘at risk’ primary prevention pathway in the middle
and the red ‘has a pressure ulcer’ secondary prevention/
treatment pathway on the right. Confusion regarding
this was highlighted by one participant as below:
Think aloud participant - ‘there is a box of where a pa-
tient is at risk, you know … the orange box where I’ve
ticked … and because it comes first then I would have auto-
matically ticked it and not bothered to look at the pink box.
It’s not very clear … well, it’s not clear at all. So, I mean …
probably, I don't know, swap it round so that … or, you
know, from top to bottom, so you look through the higher
risk, the red bit is first, then if red is not ticked, people will
go down to the orange one…’.
The boxes were subsequently re-ordered so that the
red was left (and therefore first), amber middle and blue
right [8]. The blue box was changed to green following a
subsequent pre-test cycle in line with other clinical as-
sessments which incorporate red, amber, green (RAG)
formats.
There were other examples of the two approaches (focus
groups and think aloud interviews) providing complemen-
tary insights. When considering item wording the focus
groups highlighted general issues relating to acceptability
of terminology while the think-aloud participants provided
more detailed information about areas of confusion. This
is shown in the examples below:
1) Focus group participant 1 – ‘The terminology’s
[primary and secondary prevention] not frequently
used, is it?’
Focus group participant 2 – ‘No, I mean it’s
something I’m quite familiar with, because I come
from a background of stroke and TIA, so we used to
use primary prevention, you know, for patients who
Table 3 Overall total Item completion for assessments
Pre-test 1: (TVN/RNs)
Items completed




Overall total Item completion for assessments
Total item completion for assessments concluding at step1 76.2% (32/42) 96.7% (29/30) 95.8% (23/24)
Total item completion for assessments including step 1 and 2 78.5% (740/943) 81.7% (461/564) 96.6% (566/586)
Overall total item completion 78.4% (772/985) 82.5% (490/594) 96.6% (589/610)
Overall total Item completion for assessments with decision
pathway allocated
Total item completion for assessments concluding at step1
where decision pathway allocated
0% 96.7% (29/30) 100% (21/21)
Total item completion for assessments including step 1 and 2
where decision pathway allocated
83.7% (417/498) 83.7% (452/540) 96.6% (566/586)
Overall total Item completion where decision pathway allocated 83.7% (417/498) 84.4% (481/570) 96.7% (587/607)






























Fig. 4 Percentage decision pathway allocated at each pre-test
session [8]
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had not had an event yet but were at risk, and then
secondary prevention for a patient who had had an
event and then. But I don’t know that it’s something
that we’d automatically think of in this [PU
management].
2) Think aloud participant - ‘So stage 2, looking at
sensory perception. Does the patient feel and respond
appropriately from pressure? There’s no indication of
any sort of neurological problems, so I would say yes,
she responds appropriately. The only thing I can think
of is I have to think twice, because it’s what I’d
describe as a double negative, it’s…. does the patient
feel and respond appropriately to discomfort…… I
mean, the sort of normal reaction is, the patient is fine
so it’s not a problem, so in my opinion just a mistake
to put a no. But…..so reading it, it’s actually yes, they
respond appropriately to discomfort’
Interviewer - so you’re perhaps used to when there’s a
yes answer, there’s a problem?
Think aloud participant - yeah, yeah. So then yeah,
you have to spend a bit of time to just think about it,
so it may be a problem when you’re doing it quickly,
I think’
The wording of the sensory perception item was chan-
ged prior to cycle 2 [8].
A more general issue highlighted by the participants
of the first pre-test focus group was that they felt there
should be some provision within step 1 of the PURPOSE-
T to enable nurses to use their clinical judgement as
detailed below:
Focus group participant - ‘We’ve always said about, you
know, these are just tools, that you should use nursing
judgement as well, is there any way you could have an
extra box that says, you know, to the nurses, in your
judgement, is this patient at risk?’ This may apply to the
severity of a risk factor (e.g. severe diabetes, perfusion
problems and severe nutritional problems) or other signifi-
cant factors which may be exceptions to the rule. Having
‘other items’ at step 1 was considered by the Working
Group but there was concern that the screening stage
could become too large [8]. Taking into account the causal
pathway for PU development [54], it was decided that it
wasn’t the presence of these factors per se that was import-
ant, rather it was the impact they may (or may not) have
on skin status and a ‘vulnerable skin’ item was therefore
added to the skin status section of the screening stage.
The focus groups also provided more insight into po-
tential future implementation issues that may arise e.g.
one participant articulated concern regarding the use of
colour in PURPOSE-T:
Focus group participant - ‘we’ve got a mega problem
in community, because our documentation has to be
photocopied and we don’t have a colour photocopier’.
Another participant highlighted the need for simplicity
to facilitate implementation:
Focus group participant - ‘it’s got to be something
that’s easier to implement, because we’re not going to
be able to train every single nurse, so you want some-
thing … although you can try and train everyone, a lot
of them aren’t going to have time to be relieved from
the ward for training, so it’s something that they should
be able to just pick up and start doing easily …’
The quantitative data analysis was useful in assessing
the impact of the changes to data completion and path-
way allocation over the three pre-test cycles (Tables 2,
3and 4) [8]. Figure 3 illustrates how the levels of missing
data decreased over the 3 pre-test cycles overall and
where a decision pathway was allocated. Figure 4 illustrates
how the number of decision pathways allocated increased
from the first to the second pre-test cycle. Table 4 presents
the appropriateness of the decision pathways allocated ac-
cording to the item responses for each assessment and
compliance with the decision rules of PURPOSE-T.
Review by PURSUN and Expert Group
The review of the PURPOSE-T by PURSUN UK and the
expert group following the third pre-test cycle led to a final
change to the PURPOSE-T. While PURSUN felt that the
PURPOSE-T was clear and understandable, they raised
concern about the wording of the sensory perception item
relating to the ‘ability to feel and respond’ aspect of the
item [8]. The group agreed that the patient would be at risk
of PU development if they fulfilled one component of ‘abil-
ity to feel and respond’, but the wording suggested that it
would only be a risk if both applied to the patient. They felt
that the terminology should be ‘feel and/or respond’ [8].





Pre-Test Session 3 (Sisters)
Appropriate pathway allocation 78.6% (11/14) 91.4% (32/35) 90.6% (29/32)
Inappropriate pathway allocation 7.1% (1/14)
Pathway allocated but some uncertainty of
appropriateness due to missing data items
14.3% (2/14) 8.6% (3/35) 9.4% (3/32)
TVN Tissue Viability Nurse, RN research nurse
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This led to the rewording of the sensory perception item at
the subsequent expert group meeting.
Discussion
By using cognitive pre-testing methods we were able to
assess and improve the usability and confirm the content
validity of a new evidence-based RAI with clinical nurses
over the course of three cycles. Pre-testing was particularly
important given the increased support for decision making
and instructions that are integrated in the PURPOSE-T.
Nurse insights captured in the focus group discussions/
think aloud interviews and measurement of instrument
item level completion and appropriate pathway allocation
facilitated the identification of areas of confusion. The
combined methods ensured that all aspects of usability
were considered and led to key changes to PURPOSE-T in
three main areas including the flow and format, decision
support and the wording of specific items. The pre-test
was an important methodological step to instrument
development and led to the preliminary PURPOSE-T in
readiness for onward clinical evaluation of reliability
and validity. This is the first study that we have been
able to identify which fully reports pre-testing as a key
methodological component in the development of a PU
RAI and is underpinned by methodologies used in the
development of other health measurement Instruments
and patient reported outcome measures [14, 17, 25, 26,
55]. The involvement of clinical nurses has only been
reported briefly in the literature for other RAI develop-
ment [33–36] and evidence of service user involvement
is lacking [16]. Previous developed instruments used
methods which did not incorporate structured pre-
testing methods as used in the development of
PURPOSE-T and reported in this study. These could be
important omissions as we found using a structured ap-
proach to assess and improve the usability and confirm
the content validity [17] of PURPOSE-T with clinical
nurses informative, potentially impacting on its even-
tual implementation in clinical practice.
The approach was supported by the involvement of
PURSUN in developing realistic vignettes and reviewing
PURPOSE-T following pre-testing, which led to import-
ant changes to shape the instrument. The acceptability
of PURPOSE-T to patients and carers is important as
risk assessment should involve consultation with the pa-
tient to facilitate shared decision making about risk and
the use appropriate preventative interventions [56].
To support the aims of the pre-test, purposive sam-
pling was used to target nurses from acute hospital and
community settings, with a range of job roles (i.e. Tissue
Viability Nurses, Staff Nurses and Sisters/Charge Nurses)
and an interest in tissue viability. The age range and
gender of nurse participants largely reflects national work-
force trends [57], though in keeping with other research
ethnic minorities were under represented [58–61]. It is
unclear whether this impacted the usability issues
raised in the pre-test, though the ongoing evaluation of
PURPOSE-T will involve testing with a larger number
of nurses in clinical practice and give further opportun-
ity for instrument refinement.
Nurses being grouped in similar roles, prevented hier-
archical issues impeding group member involvement in the
cycles and was felt to facilitate greater disclosure [49, 50].
The order of the pre-test cycles (in terms of nurse job roles)
was carefully considered to ensure usability issues were
identified as quickly as possible, so that changes could be
made to the draft PURPOSE-T and pre-tested in the subse-
quent cycle. The TVNs pre-test cycle was conducted first
as it was anticipated that as specialist nurses in the PU field,
they were best placed to identify any subject specific and
key usability issues which could be addressed in subse-
quent versions. Additionally, the third and last pre-test
cycle deliberately involved Sister/charge nurses so that
PURPOSE-T (incorporating changes that were made in
response to pre-test 1 and 2) could be considered by se-
nior nurses responsible for patient care. The chosen
order (of the nurses job role) was associated with a the
decreasing number of changes made to the PURPOSE-T
(Fig. 2) which is also indicative that saturation had been
reached. However in the absence of comparisons with
other role-orders we cannot determine if this could be at-
tributed to this particular order.
The use of both focus groups and think-aloud inter-
views is unusual for evaluation purposes, but this is mainly
due to differences in backgrounds and cultures of re-
searchers which use the techniques (Willis 2005). The use
of both techniques in the context of developing the
PURPOSE-T was advantageous as while there was some
overlap between the groups in terms of the nature of the
issues raised (i.e. both groups identified issues relating to
specific usability and wider application), they provided
complementary insights. As previously noted by others
the think-aloud interviews most consistently highlighted
specific usability issues (e.g. relating to the wording of
specific items) while the focus groups most consistently
identified general level usability issues relating to the
wider application/implementation of PURPOSE-T in clin-
ical practice [47, 48]. In addition, the completion of 3
PURPOSE-T assessments by each participant and descrip-
tive analysis of data completeness, highlighted problems
with particular item completion and was useful in asses-
sing the impact of the changes between versions. The
methods used in this pre-test may have wider application,
in the development and evaluation of other health related
instruments.
PURPOSE-T proposes a new approach to PU risk as-
sessment based on up to date evidence and robust devel-
opment methods. Key features of PURPOSE-T include a
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screening stage to quickly screen out those not at risk, the
inclusion of skin status to allow the distinction between
those at risk who require primary prevention and those
with an existing ulcer (or scarring from a previous ulcer)
who require secondary prevention/treatment, and the use
of colour, rather than traditional numerical scores to sup-
port pathway allocation and decision making. Future stud-
ies are required to evaluate whether the use of PURPOSE-
T encourages individualised care planning in response to
the patients specific risk profile and its impact on care
processes and outcomes.
Limitations
It could be argued that undertaking a pre-test using vignette
case studies, is no substitute for assessing the PURPOSE-T
in clinical practice. A limitation of this approach, with vi-
gnettes, is that is an artificial situation and it is acknowl-
edged that participants may have responded differently in a
real life situation [62]. However, the need to assess and im-
prove the acceptability of the PURPOSE-T with clinical
nurses was considered a robust and logical step to ensure
content validity and usability, prior to evaluation in clinical
practice with patients. In addition, the vignettes were co-
developed by the project lead, the Working Group and
members of PURSUN to ensure they were realistic, clinically
relevant and to give an indication of external validity [63].
The use of vignettes has been used previously by social sci-
entists in various fields [63], in dental, medical and nursing
education [64–66] and to establish the validity of RAIs [67,
68]. In keeping with those who have used vignettes previ-
ously, the present study, benefitted from the approach,
allowing exploration of participants knowledge, attitudes
and how they might respond to a simulated event [62, 69].
In this study the transcription data from the focus
groups and one-to-one think aloud interviews were manu-
ally coded and it might be argued that qualitative data
software would have been a more robust means of man-
aging transcription data. This relates to the assertion that
the software packages provide a more transparent, audit-
able approach to coding which provides the basis for es-
tablishing credibility, though there is concern that use of
such software encourages a focus on quantity and breadth
rather than depth and this can distance the researcher
from the data [70]. The decisions regarding qualitative
software utilisation are influenced by the size and scope of
the project and the expertise of the researcher [70, 71]. As
the scope and size of this study was quite focussed, the
use of manual data coding with summary reports being
checked by other researchers involved in the process was
considered an appropriate approach.
Conclusion
This is the first study we are aware of that incorporates
pre-testing with clinical nurses and the involvement of
service users in the development of a RAI. The pre-test
was an important development stage of this new instru-
ment as it allowed important usability issues to be identi-
fied and addressed, and content validity to be confirmed
with its intended end users. This was facilitated by the use
of realistic vignettes that were co-developed with service
users. While there was some overlap between the discus-
sions of the focus groups and one-to-one think-aloud in-
terviews, overall they were found to be complementary.
The methods described in this pre-test may have wider
health related instrument development application.
The pre-test led to the development of a preliminary
PURPOSE-T in readiness for subsequent clinical evalu-
ation to assess the validity and reliability of the RAI in
practice. PURPOSE-T proposes a new approach to PU
risk assessment, incorporating a screening stage to quickly
screen out those not at risk and the use of colour to sup-
port pathway allocation and decision making. PURPOSE-
T also incorporates skin status to facilitate a distinction
between those who require primary prevention and
those who require secondary prevention/treatment. Fur-
ther study is needed to assess whether anticipated benefits
of PURPOSE-T, including individualised care planning will
lead to improved care processes and outcomes.
Abbreviations
PU: Pressure ulcer; PURPOSE-T: Pressure ulcer risk primary or secondary
evaluation tool; PURSUN: Pressure Ulcer Research Service User Network;
PPI: Patient and public involvement; RAI: Risk assessment instrument;
TVN: Tissue viability nurse
Acknowledgements
- Pressure Ulcer Research Service User Network (PURSUN).
- The clinical nurses who participated in the Pre-Test.
Funding
This publication presents independent research funded by the National
Institute for Health Research (NIHR) under its Programme Grants for Applied
Research Programme (RP-PG-0407-10056). The views expressed in this
publication are those of the author(s) and not necessarily those of the NHS,
the NIHR or the Department of Health.
Availability of data and materials
The datasets used and/or analysed during the current study available from
the corresponding author on reasonable request.
Authors’ contributions
I can confirm that all authors including SC, JN, JK, DM, LW, EMcG, NS, CD and
EAN, have have agreed on the final version and meet the following criteria
[recommended by the ICMJE (http://www.icmje.org/recommendations/
browse/roles-and-responsibilities/defining-the-role-of-authors-and-
contributors.html)]: • substantial contributions to conception and design,
acquisition of data, or analysis and interpretation of data; • drafting the article
or revising it critically for important intellectual content.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Coleman et al. BMC Medical Research Methodology  (2016) 16:158 Page 11 of 13
Ethics approval and consent to participate
The study was reviewed and approved a University of Leeds School of
Healthcare Ethics Committee. All participants provided written informed
consent prior to participation in the study.
Author details
1Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.
2Leeds Institute of Health Sciences, University of Leeds, Leeds, UK. 3Mid
Yorkshire Hospital NHS Trust, Wakefield, UK. 4Leeds Teaching Hospitals NHS
Trust, Leeds, UK. 5Wound Prevention and Management Service, Leeds
Community Healthcare NHS Trust, Leeds, UK. 6School of Health & Population
Sciences, University of Birmingham, Birmingham, UK. 7School of Healthcare,
University of Leeds, Leeds, UK.
Received: 12 February 2016 Accepted: 3 November 2016
References
1. NPUAP/EPUAP/PPPIA, National Pressure Ulcer Advisory Panel, European
Pressure Ulcer Advisory Panel and Pan Pacific Pressure Injury Alliance. In:
Emily H, editor. Prevention and treatment of pressure ulcers: clinical practice
guideline. Obsborne Park: Cambridhe Media; 2014.
2. Gorecki C, et al. Impact of pressure ulcers on quality of life in older patients:
a systematic review. J Am Geriatr Soc. 2009;57(7):1175–83.
3. Gorecki C, et al. What influences the impact of pressure ulcers on health-
related quality of life? A qualitative patient-focused exploration of
contributory factors. J Tissue Viability. 2012;21(1):3–12.
4. Severens JL, et al. The cost of illness of pressure ulcers in The Netherlands.
Adv Skin Wound Care. 2002;15(2):72–7.
5. Schuurman J-P, et al. Economic evaluation of pressure ulcer care: a cost
minimization analysis of preventive strategies. Nurs Econ. 2009;27(6):390–400.
6. Berlowitz, D., et al. Preventing Pressure Ulcers in hospitals: A toolkit for improving
quality of care. 2011. DOI: AHRQ (Agency of Healthcare Research and Quality).
7. Dealey C, Posnett J, Walker A. The cost of pressure ulcers in the United
Kingdom. J Wound Care. 2012;21(6):261–6.
8. Nixon, J., et al. Pressure UlceR Programme Of reSEarch (PURPOSE): using
mixed methods (systematic reviews, prospective cohort, case study,
consensus and psychometrics) to identify patient and organisational risk,
develop a risk assessment tool and patient-reported outcome Quality of Life
and Health Utility measures. Programme Grants Appl Res 2015. 3(6).
9. NPUAP/EPUAP. Prevention and treatment of pressure ulcers:clinical practice
guideline. Washington DC: National Pressure Ulcer Advisory Panel; 2009.
10. NICE, Pressure ulcer prevention: the prevention and management of
pressure ulcers in primary and secondary care, Clinical Guideline 179,
Methods, evidence and recommendations. NICE: National Clinical Guideline
Centre, 2014
11. Beeckman D, et al., A National Guideline for the prevention of pressure
ulcers: Good Clinical Practice (GCP), KCE Reports 193C. Belgian Health Care
Knowledge Centre (KCE): Belgian Health Care Knowledge Centre (KCE).
2013.
12. AHCPR. Pressure ulcers in adults: prediction and prevention. Quick reference
guide for clinicians. Rockville: US Department of Health and Human
Services; 1992.
13. NICE. In: NICE, editor. CG7 pressure relieving devices. London: National
Institute of Clinical Excellence; 2003.
14. SAC. Assessing health status and quality-of-life instruments: attributes and
review criteria. Qual Life Res. 2002;11:193–205.
15. Gorecki, C., The development and validation of a patient-reported outcome
measure of health-related quality of life for patients with pressure ulcers:
PUQOL Project. PhD Thesis, University of Leeds, 2011.
16. Coleman S. The development of a pressure ulcer risk assessment framework
and minimum data set, in School of Healthcare. Leeds: University of Leeds; 2014.
17. FDA DHHS, Guidance for Industry: Patient-Reported Outcome Measures: Use in
Medical Product Development to Support Labeling Claims http://www.fda.
gov/downloads/Drugs/GuidanceComplianceRegulatory/
InformationGuidances/UCM193282.pdf. 2009. (Accessed March 2014)
18. Bridel J. Risk assessment. J Tissue Viability. 1994;4(3):84–5.
19. Cullum, N., et al. The Prevention and Treatment of Pressure Sores: how
useful are the measures for scoring people’s risk of developing a pressure
sore? 1995, Effective Health Care Bulletin p. 1–18
20. Nixon J, McGough A. Principles of patient assessment: screening for
pressure ulcers and potential risk. In: Morison M, editor. The prevention and
treatment of pressure ulcers. 1st ed. Edinburgh: Mosby; 2001. p. 55–74.
21. Boult M, et al. Developing tools to predict outcomes following cardiovascular
surgery. ANZ J Surg. 2011;81(11):768–73.
22. Steyerberg E. In: Gail M et al., editors. Clinical prediction models: a practical
approach to development, validation, and updating. New York: Springer; 2010.
23. Greenhalgh J, et al. Reviewing and selecting outcome measures for use in
routine practice. J Eval Clin Pract. 1998;4(4):339–50.
24. Liu J, Wyatt J, Altman D. Decision tools in health care: focus on the
problem, not the solution. BMC Med Inform Decis Mak. 2006;6(1):1–7.
25. Rothman M, et al. Use of existing patient-reported outcome (PRO)
instruments and their modification: the ISPOR Good Research Practices for
Evaluating and Documenting Content Validity for the Use of Existing
Instruments and Their Modification PRO Task Force Report. Value Health.
2009;12(8):1075–83.
26. Gorecki C, et al. Applying mixed methods to pretest the Pressure Ulcer
Quality of Life (PU-QOL) instrument. Qual Life Res. 2012;21(3):441–51.
27. Coleman S, et al. Patient risk factors for pressure ulcer development:
systematic review. Int J Nurs Stud. 2013;50(7):974–1003.
28. Braden B, Bergstrom N. A conceptual schema for the study of the etiology
of pressure sores. Rehabil Nurs. 1987;12(1):8–16.
29. Suriadi Y, et al. Development of a new risk assessment scale for predicting
pressure ulcers in an intensive care unit. Nurs Crit Care. 2008;13(1):34–43.
30. Norton D, McClaren R, Exton-Smith AN. An investigation of geriatric nursing
problems in hospital. London: Churchill Livingstone; 1962.
31. Gosnell DJ. An assessment tool to identify pressure sores. Nurs Res.
1973;22(1):55–9.
32. Andersen KE, et al. Prevention of pressure sores by identifying patients at
risk. Br M J Clin Res. 1982;284(6326):1370–1.
33. Abruzzese RS. Early assessment and prevention of pressure sores. In: Lee BY,
editor. Chronic ulcers of the skin. New york: McGraw-Hill; 1985. p. 1–19.
34. Waterlow J. Pressure sores: a risk assessment card. Nurs Times.
1985;81(48):49–55.
35. Pritchard V. Pressure sores. Calculating the risk. Nurs Times. 1986;82(8):59–61.
36. Cubbin B, Jackson C. Trial of a pressure area risk calculator for intensive
therapy patients. Intensive Care Nurs. 1991;7(1):40–4.
37. Song M, Choi KS. Factors predicting development of decubitus ulcers
among patients admitted for neurological problems. Kanho Hakhoe Chi.
1991;21(1):16–26.
38. Lindgren M, et al. A risk assessment scale for the prediction of pressure sore
development: reliability and validity. J Adv Nurs. 2002;38(2):190–9.
39. Kwong E, et al. Predicting pressure ulcer risk with the modified Braden,
Braden, and Norton scales in acute care hospitals in Mainland China. Appl
Nurs Res. 2005;18(2):122–8.
40. Perneger TV, et al. Screening for pressure ulcer risk in an acute care hospital:
development of a brief bedside scale. J Clin Epidemiol. 2002;55(5):498–504.
41. Page KN, Barker AL, Kamar J. Development and validation of a pressure
ulcer risk assessment tool for acute hospital patients. Wound Repair Regen.
2011;19(1):31–7.
42. Coleman S, et al. Developing a pressure ulcer risk factor minimum data set
and risk assessment framework. J Adv Nurs. 2014;70(10):2339–52.
43. Coleman, S., et al. A New Pressure Ulcer Conceptual Framework Journal of
Advanced Nursing 2014. DOI: 10.1111/jan.12405
44. Collins D. Pretesting survey instruments: an overview of cognitive methods.
Qual Life Res. 2003;12(3):229–38.
45. Kitzinger J. Qualitative research. Introducing focus groups. BMJ.
1995;311(7000):299–302.
46. Ericcson K, Simon H. Verbal reports as data. Psychol Rev. 1980;87(3):215–51.
47. Snijkers G. Cognitive laboratory experiences: On pretesting computerised
questionnaires and data quality. Netherlands: Uttrecht University; 2002.
48. Willis GB. Cognitive interviewing: a tool for improving questionnaire design.
Thousand Oaks: Sage Publications; 2005.
49. Morgan DL, Krueger RA. When to use focus groups and why. In: Morgan D,
editor. Successful focus groups: advancing the state of the art. London: Sage;
1993. p. 3–19.
50. McColl E. Developing questionnaires. In: Fayers P, Hays R, editors. Assessing
quality of life in clinical trials. 2nd ed. New York: Oxford University Pres;
2005.
51. Krueger RA. Focus groups: a practical guide for applied research. 2nd ed.
Thousand Oaks: Sage; 1994.
Coleman et al. BMC Medical Research Methodology  (2016) 16:158 Page 12 of 13
52. Hughes R, Huby M. The application of vignettes in social and nursing
research. J Adv Nurs. 2002;37(4):382–6.
53. Hsieh HF, Shannon SE. Three approaches to qualitative content analysis.
Qual Health Res. 2005;15(9):1277–88.
54. Coleman S, et al. A new pressure ulcer conceptual framework. J Adv Nurs.
2014;70(10):2222–34.
55. Streiner D, Norman G. Health measurement scales: a practical guide to their
development and use. 4th ed. New York: Oxford University Pres; 2008.
56. Coleman S, et al. Patient involvment in risk tool development. Nurs Times.
2015;111(25):17–9.
57. HSCIC, NHS Workforce statistics, provisional statisitcs http://www.hscic.gov.
uk/searchcatalogue?productid=21281&returnid=1907, H.a.S.C.I. Centre,
Editor. 2016. Accessed Aug 2016.
58. Sheikh A, et al. Recruitment of ethnic minorities to asthma studies. Thorax.
2004;59(7):634.
59. Hussain-Gambles M, Atkin K, Leese B. Why ethnic minority groups are
under-represented in clinical trials: a review of the literature. Health Soc
Care Community. 2004;12(5):382–8.
60. Brown G, et al. Barriers to recruiting ethnic minorities to mental health
research: a systematic review. Int J Methods Psychiatr Res. 2014;23(1):36–48.
61. Dhaliwal S, McKay S. The worklife experiences of black nurses in the NHS. A
Report for the Royal College of Nursing. London: RCN; 2008. https://www2.
rcn.org.uk/__data/assets/pdf_file/0004/164146/003249.pdf.
62. Lanza ML. A methodological approach to enhance external validity in
simulation based research. Issues Ment Health Nurs. 1990;11(4):407–22.
63. Flaskerud JH. Use of vignettes to elicit responses toward broad concepts.
Nurs Res. 1979;28(4):210–2.
64. Littlefield JH, et al. A multimedia patient simulation for teaching and
assessing endodontic diagnosis. J Dent Educ. 2003;67(6):669–77.
65. Dillon GF, et al. Simulations in the United States Medical Licensing
Examination (USMLE). Qual Saf Health Care. 2004;13 Suppl 1:i41–5.
66. Goodstone L, et al. Effect of simulation on the development of critical
thinking in associate degree nursing students. Nurs Educ Perspect.
2013;34(3):159–62.
67. Gould D, et al. Establishing the validity of pressure ulcer risk assessment
scales: a novel approach using illustrated patient scenarios. Int J Nurs Stud.
2002;39(2):215–28.
68. Gould D, et al. Examining the validity of pressure ulcer risk assessment
scales: a replication study. Int J Nurs Stud. 2004;41(3):331–9.
69. Gould D. Using vignettes to collect data for nursing research studies: how
valid are the findings? J Clin Nurs. 1996;5(4):207–12.
70. St John W, Johnson P. The pros and cons of data analysis software for
qualitative research. J Nurs Scholarsh. 2000;32(4):393–7.
71. Basit T. Manual or electronic? The role of coding in qualitative data analysis.
Educ Res. 2003;45(2):143–54.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Coleman et al. BMC Medical Research Methodology  (2016) 16:158 Page 13 of 13
